Vogenx, Inc. (VOGX) stock
VOGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026
$12.34−1.14 (-8.46%)
Close on Nov 18, 2026Market cap $183.31MP/E –Yield –
Vogenx operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
No operating income figures for Vogenx
Vogenx has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?